Cas:1502-24-5 2,3-dimethylcyclohexan-1-ol manufacturer & supplier

Chemical Name:2,3-dimethylcyclohexan-1-ol

CAS.NO:1502-24-5

Synonyms:3-Hydroxy-1.2-dimethyl-cyclohexan;Cyclohexanol,2,3-dimethyl;2,3-Dimethylcyclohexanol;2,3-DiMethylcyclohexanol;2,3-dimethyl-1-cyclohexanol

Molecular Formula:C₈H₁₆O

Molecular Weight:128.21200

HS Code:2906120090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:182.4ºC at 760 mmHg

Density:0.893 g/cm3

Index of Refraction:n20/D 1.465(lit.)

PSA:20.23000

Exact Mass:128.12000

LogP:1.80340

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-Hydroxy-1.2-dimethyl-cyclohexan chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,3-dimethyl-1-cyclohexanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Hydroxy-1.2-dimethyl-cyclohexan Use and application,3-Hydroxy-1.2-dimethyl-cyclohexan technical grade,usp/ep/jp grade.

Related News: As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. 2,3-dimethylcyclohexan-1-ol manufacturer Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: ��Within the top 20 global companies that spent the most on R&D in 2018, the top spender �C despite having the second smallest annual revenue of the group at $15.28 billion �C is Celgene, whose R&D spend was equal to 37% of its annual revenue. 2,3-dimethylcyclohexan-1-ol supplier As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. 2,3-dimethylcyclohexan-1-ol vendor As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. 2,3-dimethylcyclohexan-1-ol factory In recent years, with the increasing number of patent medicines whose patents have expired, the variety and quantity of generic drugs have also increased rapidly, which has brought huge market opportunities to the API market and the output of APIs has continued to increase.